EP2437721A2 - Composition cosmétique à base d'ester d'opc de pin - Google Patents
Composition cosmétique à base d'ester d'opc de pinInfo
- Publication number
- EP2437721A2 EP2437721A2 EP10734197A EP10734197A EP2437721A2 EP 2437721 A2 EP2437721 A2 EP 2437721A2 EP 10734197 A EP10734197 A EP 10734197A EP 10734197 A EP10734197 A EP 10734197A EP 2437721 A2 EP2437721 A2 EP 2437721A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- cosmetic composition
- composition according
- esterified
- skin
- oligomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9767—Pinaceae [Pine family], e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Definitions
- the invention relates to a cosmetic composition for repairing and possibly preventing the effects of aging of the skin based on a maritime pine bark extract whose procyanidolic oligomers (OPC) are esterified with a fatty acid.
- OPC procyanidolic oligomers
- ProCyanidolic Oligomers also called proanthocyanidins or proanthocyanidic oligomers, are natural molecules that are widely used in nature. Indeed, they are found in vegetables, fruits, cereals but also in grape seeds and pine bark. The nutritional and physiological interest of these molecules is related to their antioxidant properties and their benefit on the cardiovascular system.
- OPCs belong to the chemical family of polyphenols and more particularly to the class of flavonoids, compounds known for their antioxidant properties.
- the OPCs consist of one or more repeating monomeric units of flavan-3-ol, which units are independently selected from catechin, or epicatechin or epicatechin gallate. These units are usually repeated 2 to 4 times, the most common OPCs being generally in dimer form.
- OPC procyanidolic oligomers
- the present invention thus relates to a cosmetic composition for repairing the effects of skin aging comprising: a) procyanidolic oligomers (PCOs) extracted from pine bark, said oligomers being esterified with at least one fatty acid; and b) a cosmetically acceptable vehicle.
- PCOs procyanidolic oligomers
- the cosmetic compositions according to the invention comprise: a) a pine bark extract whose procyanidolic oligomers (OPC) are esterified with at least one fatty acid, and b) a cosmetically acceptable vehicle.
- OPC procyanidolic oligomers
- cosmetically acceptable vehicle is meant a vehicle adapted for use in contact with human and animal cells, in particular the cells of the epidermis, without toxicity, irritation, undue allergic response and the like, and proportionate to an advantage ratio. / reasonable risk.
- Extracts of pine bark, especially maritime contain a large variety of procyanidolic oligomers, including catechin monomers, and taxifoliol, as well as procyanidol oligomers of 2 to 5 flavan-3-ol units, the monomers and the dimers being predominantly present.
- the composition of pine bark extracts is qualitatively and / or quantitatively different from that of other extracts of plant origin, in particular grape seed extracts, which are found in particular in the trade under the name VITAFLAVAN ®.
- the procyanolidic oligomers extracted from pine bark comprise in particular taxifoliol, taxifoliol glucoside, ferulate glucoside and various phenolic acids, which are not present in grape seed extracts. Unlike these, they do not include epicatechin or epicatechin gallate.
- OPCs generally account for about 70% by weight of the total weight of pine bark extract.
- Maritime pine bark extracts are commercially available
- the pine bark extract may be in particular a French maritime pine (Pinus pinaste®) extract, such as the Austin pine,
- the procyanidolic oligomers (OPC) contained in the extracts of maritime pine bark are esterified with a fatty acid according to the process described in the patent application FR 2 723 943.
- the OPC are esterified according to the process comprising the steps of: a) contacting the extract of maritime pine bark in a non-solvent liquid medium for said extract but solvent for the esters to be obtained, so as to obtain a suspension; b) adding to said suspension at least one low-boiling aliphatic tertiary amine, in the presence of a catalytic amount of at least one organic base other than pyridine, and c) introducing into this mixture from least one fatty acid chloride, the reaction mixture being stirred at a temperature below 4O 0 C and then concentrated by evaporation to obtain an extract including the OPC are esterified.
- the OPCs are esterified with saturated fatty acids, in particular palmitic acid and stearic acid, more preferentially palmitic acid.
- composition according to the invention is carried out topically.
- composition is intended more particularly for the treatment of the skin and may be in the form of ointment, cream, oil, milk, ointment, powder, impregnated buffer, solution, gel, spray, lotion, suspension, soap.
- compositions according to the invention can be cosmetic compositions in the form of oil-in-water or water-in-oil emulsion, or multiple emulsions, microemulsion, hydroalcoholic gel, cream, oil of hydroalcoholic lotion.
- the cosmetic compositions according to the invention may comprise from 0.1 to 2.5% of said esterified extract expressed by weight relative to the total weight of the composition, preferably from 0.2 to 1.0%.
- the cosmetic compositions according to the invention are particularly useful for increasing collagen synthesis, in particular by human dermal fibroblasts. They are also advantageously useful for soothing the skin, and / or for protecting the skin against free radicals. They are thus particularly useful for preventing the effects of skin aging, especially photoaging.
- the invention also relates to the use of a cosmetic composition
- a cosmetic composition comprising: a) procyanidolic oligomers (PCOs) extracted from pine bark, said oligomers being esterified with at least one fatty acid; and b) a cosmetically acceptable vehicle for repairing the effects of skin aging.
- PCOs procyanidolic oligomers
- the present invention also relates to a cosmetic treatment method, comprising the application, especially topical, of a cosmetic composition as defined above.
- the present invention relates to a cosmetic treatment method, for repairing the effects of skin aging, comprising the application of a cosmetic composition comprising procyanidolic oligomers (PCOs) extracted from pine bark, said oligomers being esterified with at least a fatty acid; and a cosmetically acceptable vehicle.
- a cosmetic composition comprising procyanidolic oligomers (PCOs) extracted from pine bark, said oligomers being esterified with at least a fatty acid; and a cosmetically acceptable vehicle.
- PCOs procyanidolic oligomers
- the present invention also relates to a cosmetic treatment method, for repairing the effects of skin aging, comprising the application of a cosmetic composition comprising a pine bark extract whose procyanidolic oligomers (OPC) are esterified with at least one acid fat, and a cosmetically acceptable vehicle.
- a cosmetic treatment method for repairing the effects of skin aging, comprising the application of a cosmetic composition comprising a pine bark extract whose procyanidolic oligomers (OPC) are esterified with at least one acid fat, and a cosmetically acceptable vehicle.
- OPC procyanidolic oligomers
- the pine bark extract (Oligopin ®) is esterified with palmitic acid according the method described in patent application FR 2,723,943.
- pine OPC esters refer to the esterified pine bark extract according to the present example 1.
- the purpose of this study is to evaluate, by an in vitro test, the ability of the pine OPC esters prepared according to Example 1 to induce cytotoxic effects on a monolayer of human fibroblasts.
- the objective of the study is to evaluate the ability of pine OPC esters to induce cytotoxic effects on a primary culture of normal human fibroblasts. After application of the product to cells for 24 hours, cell viability is assessed by measuring the activity of mitochondrial succinate dehydrogenase in living cells. This enzyme transforms MTT (3 (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) into blue formazan crystals. After dissolution of these crystals, a spectrophotometric reading is carried out. The measured absorbances are proportional to the number of living cells.
- the cells used are fibroblasts of human skin tissue (prepuce Caucasian child), passing 1. 4. Conduct of the study
- the positive control has a mortality greater than 30%, this validates the test.
- the pine OPC esters according to Example 1 do not exhibit a significant cytotoxic effect.
- the maximum concentration used should be 1000 ⁇ g / ml.
- a human epidermis is reconstituted in vitro in culture inserts.
- a disk of filter paper is deposited on the "stratum corneum” on which the substance under test has been deposited (preventive treatment). 24 hours later, the UVB is irradiated and then the substance is again applied to the test (curative treatment). 24 hours later, we realize:
- an MDA malonaldehyde
- end product formed during the process of lipid peroxidation induced by the formation of radical species, or of species activated by oxygen end product formed during the process of lipid peroxidation induced by the formation of radical species, or of species activated by oxygen.
- the keratinocytes are inoculated at the density of 100 ⁇ 10 3 cells / cm 2 in inserts whose bottom consists of a polycarbonate membrane (porosity 0.4 ⁇ m-1 cm 2 ).
- the cells are incubated at 37 ° C. in a humid atmosphere containing 5% (v / v) of CO 2 for 24 hours, in the "immersed" situation in the culture medium: MCDB / 153 supplemented with EGF (5 ng / ml) mL), insulin (5 ⁇ g / mL), hydrocortisone (0.5 ⁇ g / mL), BPE (70 ⁇ g / mL).
- the culture medium is replaced by the same culture medium supplemented with 1 mM Ca ++ to induce the stratification of the monolayer in "immersed situation" for 6 days.
- the culture medium is changed every three days.
- the epidermal sheet is set "position emerged" the 6th day, that is to say that it is not nurtured only through the basal cells, the stratum corneum being exposed to air.
- the culture medium is changed every three days.
- the culture medium is changed and replaced by the same culture medium supplemented with 1% antibiotics (10,000 U Penicillin - 10,000 ⁇ g / mL Streptomycin - 25 ⁇ g / mL Amphotericin) 20 ⁇ L of the test substance (3 non-cytotoxic concentrations), or 20 ⁇ L of the negative controls (culture medium) or solvent controls are applied under sterile conditions on a filter paper disc (Whatman # 3MMChr) covering the surface of the reconstructed epidermis, the side on which the test substance was deposited, and the controls in contact with the stratum corneum.
- antibiotics 10,000 U Penicillin - 10,000 ⁇ g / mL Streptomycin - 25 ⁇ g / mL Amphotericin
- 20 ⁇ L of the test substance 3 non-cytotoxic concentrations
- solvent controls are applied under sterile conditions on a filter paper disc (Whatman # 3MMChr) covering the surface of the reconstructed epidermis, the side on which the test substance was deposited,
- test substance series (5, 50 and 500 ⁇ g / mL) consisting of 3 epidermis each (to be irradiated),
- the first eight series are incubated for 24 hours at 37 ° C. in a humid atmosphere containing 5% (v / v) of CO 2 (preventive treatment for the treated series).
- the ninth series corresponding to the positive control 2 (Indomethacin), consists of depositing 20 ⁇ l of a solution of indomethacin at 10 ⁇ g / ml on a disk of filter paper (Whatmann No. 3 MMChr) deposited in contact with the epidermis reconstructed and incubated for 3 hours at 37 ° C, 21 h after the implementation of the previous series.
- the curative treatment is then carried out as described above for the preventive treatment over a period of 24 hours, except for the positive control series 2
- MTT * test The MTT test is performed according to the conditions described in the Hausen M. B, Nielsen SE and Berg K. Re-examination and further development of a precise and rapid dyemethod for measuring cell growth / cell kill. J. Immunol. Methods. 1989, 19, 203; and Mosmann T., Rapid Colorimetric Assay for Cell Growth and Survival: Application to Proliferation and Cytotoxic Assays, J. Immunol. Methods. 1983, 65, 55-63. At the end of the incubation time chosen, the Whatman paper disc is carefully removed, the "stratum corneum” rinsed, and the porous membrane bearing the epidermal sheet is detached from the insert using a scalpel. The culture media used for the determination of IL-1 ⁇ I 1 and MDA.
- the epidermal leaflet is: - rinsed with PBS (2 times),
- dilutions are carried out between 0.1 and 10 ⁇ M (0.1 - 1 - 2.5 - 5 and 10 ⁇ M).
- 500 ⁇ L of culture medium (or 500 ⁇ L of standard range) are vigorously mixed with the Vortex to 1 mL of a "TCA, TBA, HCI” (TCA (trichloroacetic acid) 0.15% (w / v) solution, of 0.35% (w / v) TBA (2-thiobarbituric acid), 0.25 M HCl (heated at 100 ° C for 15 minutes to dissolve the TBA, and then allowed to cool).
- TCA trichloroacetic acid
- Irradiated absolute negative control A decrease of 37% (P ⁇ 0.05) of the OD (UA MTT) compared with the absolute negative control is observed, which corresponds to the cytotoxic effect generally obtained for the dose of irradiation used (0.6 J / cm 2 ) and validates the irradiation.
- the solvent control it did not significantly modify cell proliferation.
- the irradiated solvent control it is not significantly different from the irradiated absolute negative control.
- Irradiated absolute negative control The level of IL-1 ⁇ in the culture medium is very important: + 290% (P ⁇ 0.02) compared to the absolute negative control. This result validates the reactive system which appears particularly reactive.
- Irradiated absolute negative control treated with indomethacin 3 hours before irradiation indomethacin used as a preventive inhibits partially (-20%) the synthesis and secretion of IL-1 ⁇ in the culture medium. Although not statistically significant, this effect corresponds to the values usually obtained.
- the irradiated absolute negative control the MDA level is increased by 175% (P ⁇ 0.02) compared to the absolute non-irradiated negative control, which validates the reagent system.
- the irradiated solvent control it has no significant effect on the level of MDA, relative to the absolute negative control irradiated.
- test element pine OPC esters of Example 1
- Fibroblasts are the main cells of the dermis. They are specialized in the synthesis of two types of protein fibers: collagen fibers and elastin fibers constituents of the extracellular matrix. Collagen is 70% of the dermis proteins and gives it resistance to tension and traction. The objective of this study is to evaluate the effect of the test element on collagen synthesis after a 24-hour contact with a normal human fibroblast monolayer. 3. Test system Cells used:
- the cells used are fibroblasts of human skin tissue child (boy, Caucasian), passing 2.
- the fibroblasts are prepared and updated according to the operating procedure in force.
- the reference elements are also tested in triplicate.
- the cells are inoculated at a rate of 50,000 cells / cm 2 . After 24 hours of culture (37 ⁇ €, 5% CO 2 J, they were incubated with the product under consideration and the reference element for 24 hours in an environment of 1% FCS Determination of collagen.:
- the collagen is assayed in the extracellular matrix and in the culture medium using the Sircol assay kit, Biocolor Ltd, Ireland, according to the protocol described in the kit.
- the assay is performed using the Sirius red dye (Direct Red 80) which has a specific affinity for the triple helix structure (GIy-XY) n of native collagen.
- Sirius red dye Direct Red 80
- GIy-XY triple helix structure
- a standard curve is carried out between 0 and 50 ⁇ g / ml of type I collagen.
- the cell density is evaluated under the same conditions as above, by measuring the activity of succinate dehydrogenase mitochondrial living cells. This enzyme transforms MTT (3 (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) into blue formazan crystals. After dissolution of these crystals, a spectrophotometric reading is carried out. The measured absorbances are proportional to the number of living cells.
- the measured absorbance is expressed in units of MTT (U MTT). It is proportional to the amount of cells present in each well.
- the concentration of collagen is expressed in ⁇ g of collagen / ml / U MTT in the extracellular matrix and in the culture medium.
- TGF ⁇ 1 at 10 ⁇ g / ml significantly stimulates (38%) the total synthesis of collagen. This result validates the model used. Stimulation is particularly effective at the level of the cell matrix (88%).
- the effect is maximum for the concentrations 200 and 50 ⁇ g / ml.
- the pine OPC esters according to Example 1 have a significant effect on the synthesis of collagen.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0953620A FR2945940B1 (fr) | 2009-06-02 | 2009-06-02 | Composition cosmetique a base d'ester d'opc de pin |
PCT/FR2010/051054 WO2010139887A2 (fr) | 2009-06-02 | 2010-06-01 | Composition cosmétique à base d'ester d'opc de pin |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2437721A2 true EP2437721A2 (fr) | 2012-04-11 |
Family
ID=41664643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10734197A Withdrawn EP2437721A2 (fr) | 2009-06-02 | 2010-06-01 | Composition cosmétique à base d'ester d'opc de pin |
Country Status (7)
Country | Link |
---|---|
US (1) | US20120142767A1 (fr) |
EP (1) | EP2437721A2 (fr) |
JP (1) | JP2012528838A (fr) |
CA (1) | CA2763968A1 (fr) |
EA (1) | EA025244B1 (fr) |
FR (1) | FR2945940B1 (fr) |
WO (1) | WO2010139887A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102012223405A1 (de) | 2012-12-17 | 2014-06-18 | Henkel Ag & Co. Kgaa | Emulsion mit Oligomeren einer Flavan-3-ol-Verbindung, einer speziellen Phenylcarbonyl-Tanninverbidnung und Ginsengextrakt |
CN110755280A (zh) * | 2019-11-03 | 2020-02-07 | 广州悦荟化妆品有限公司 | 一种保湿修复手膜 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6180133B1 (en) * | 1997-11-25 | 2001-01-30 | Watson Pharmaceuticals, Inc. | Antioxidant composition for topical/transdermal prevention and treatment of wrinkles |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2723943B1 (fr) * | 1994-08-26 | 1996-10-18 | Berkem Sa | Procede d'esterification d'un extrait oligomere polyphenolique d'origine vegetale, composition ainsi obtenue et son utilisation |
FR2792530B1 (fr) * | 1999-04-21 | 2001-06-22 | Berkem Sa | Preparation d'un medicament contenant des composes polyphenoliques de type catechique ou flavoniliques d'origine vegetale, en particulier pour le traitement des gingivites |
EP1256335A1 (fr) * | 2001-05-10 | 2002-11-13 | Cognis France S.A. | Utilisation des oligomères procyanidoliques |
JP2004359640A (ja) * | 2003-06-06 | 2004-12-24 | Toyo Shinyaku:Kk | コラーゲン産生増強皮膚外用剤 |
ITFI20050029A1 (it) * | 2005-02-21 | 2006-08-22 | Genius S R L | Procedimento per arricchire ed integrare con antiossidanti organici oli di oliva e prodotto ottenuto con tale procedimento, ed impianto per attuare detto procedimento |
JP4074652B1 (ja) * | 2007-03-26 | 2008-04-09 | 株式会社フローラ | カテキン誘導体の製造方法 |
ES2635507T3 (es) * | 2010-04-12 | 2017-10-04 | Berkem S.A. | Procedimiento para la fabricación de derivados de polifenoles estabilizados |
-
2009
- 2009-06-02 FR FR0953620A patent/FR2945940B1/fr active Active
-
2010
- 2010-06-01 JP JP2012513653A patent/JP2012528838A/ja active Pending
- 2010-06-01 WO PCT/FR2010/051054 patent/WO2010139887A2/fr active Application Filing
- 2010-06-01 US US13/375,064 patent/US20120142767A1/en not_active Abandoned
- 2010-06-01 EA EA201101682A patent/EA025244B1/ru not_active IP Right Cessation
- 2010-06-01 EP EP10734197A patent/EP2437721A2/fr not_active Withdrawn
- 2010-06-01 CA CA2763968A patent/CA2763968A1/fr not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6180133B1 (en) * | 1997-11-25 | 2001-01-30 | Watson Pharmaceuticals, Inc. | Antioxidant composition for topical/transdermal prevention and treatment of wrinkles |
Non-Patent Citations (1)
Title |
---|
GRIMM TANJA; SCHAEFER ANGELIKA; HOEGGER PETRA: "Antioxidant activity and inhibition of matrix metalloproteinases by metabolites of maritime pine bark extract (pycnogenol)", FREE RADICAL BIOLOGY & MEDICINE, vol. 36, no. 6, 15 March 2004 (2004-03-15), pages 811 - 822, XP055324052, ISSN: 0891-5849, DOI: doi:10.1016/j.freeradbiomed.2003.12.017 * |
Also Published As
Publication number | Publication date |
---|---|
EA201101682A1 (ru) | 2012-09-28 |
WO2010139887A2 (fr) | 2010-12-09 |
US20120142767A1 (en) | 2012-06-07 |
CA2763968A1 (fr) | 2010-12-09 |
FR2945940A1 (fr) | 2010-12-03 |
FR2945940B1 (fr) | 2011-07-15 |
JP2012528838A (ja) | 2012-11-15 |
WO2010139887A3 (fr) | 2012-05-10 |
EA025244B1 (ru) | 2016-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1820492B1 (fr) | Composition protectrice et régénérante | |
FR3068251B1 (fr) | Composition cosmetique comprenant une huile essentielle d'immortelle et un extrait d'origanum | |
WO2018002453A1 (fr) | Composition pour lutter contre les signes du vieillissement de la peau et des phaneres | |
EP3173065A1 (fr) | Extrait alcoolique de parties aériennes de solidago virgaurea subsp. alpestris, son procédé d'obtention, et composition cosmétique ou dermatologique le contenant | |
EP1743628A1 (fr) | Composition cosmétique comprenant un extrait d'algue rouge comprenant une association de floridoside et d'acide iséthionique. | |
WO2004069218A1 (fr) | Utilisation du verbascoside comme agent stimulant la synthese de proteines de choc thermique par les cellules de la peau | |
WO2019211567A1 (fr) | Composition comprenant de l'acide alpha-lipoique ou l'un de ses sels, un derive de vitamine c et de l'acide hyaluronique et son utilisation | |
EP2763652A2 (fr) | Utilisation de glucanes obtenus a partir de prunus persica comme agent cosmetique anti-age | |
FR3053890A1 (fr) | Extrait d'aesculus hippocastanum | |
EP2437721A2 (fr) | Composition cosmétique à base d'ester d'opc de pin | |
WO2000059466A1 (fr) | Composition cosmetique comprenant un extrait lipidique de skeletonema | |
EP3638203A1 (fr) | Compositions cosmetiques comprenant des extraits naturels et leurs utilisations | |
EP2173319A2 (fr) | Composition cosmetique ayant des proprietes anti-radicalaires et procede d'application correspondant | |
FR3011008A1 (fr) | Procedes d'evaluation des effets deleteres des uv sur la peau d'enfant | |
EP3434329B1 (fr) | Utilisation cosmétique d'un extrait de tulipe sur les cheveux | |
EP0826367A2 (fr) | Utilisation d'un extrait de Bertholletia dans le domaine cosmétique ou pharmaceutique, et pour la préparation de milieux de cultures de cellules | |
FR2937545A1 (fr) | Procede de traitement cosmetique et pharmaceutique destine a reduire a la fois la synthese endogene de sirtuine et de reduire les contractions musculaires et compositions pour sa mise en oeuvre | |
FR3076461A1 (fr) | Composition cosmétique de prévention active des signes de l’âge. | |
WO2019077268A1 (fr) | Composition cosmétique de prévention active des signes de l'âge | |
FR2942721A1 (fr) | Procede de traitement cosmetique et pharmaceutique destine a reduire a la fois les rides et augmenter la fermete sans provoquer de lipolyse et compositions pour sa mise en oeuvre | |
FR2937544A1 (fr) | Procede de traitement cosmetique, pharmaceutique et dermo-cosmetique destine a reduire a la fois la synthese eudogene des sirtuine et de reduire les contactions musculaires et compositions pour sa mise en oeuvre | |
WO2022208005A1 (fr) | Composition cosmetique comprenant au moins un extrait de bouleau et au moins un extrait de bourgeon de hetre | |
EP3134100B1 (fr) | Compositions cosmetiques a application topique comprenant des cellules vegetales de bougainvillier | |
WO2022112724A2 (fr) | Extrait fermenté de miel d'ikaria | |
FR2943534A1 (fr) | Utilisation cosmetique anti-radicalaire d'un principe actif issu de myrtus communis, notamment de tanins hydrolysables d'un principe actif issu de myrtus communis. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20120102 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA RS |
|
R17D | Deferred search report published (corrected) |
Effective date: 20120510 |
|
17Q | First examination report despatched |
Effective date: 20130124 |
|
RAX | Requested extension states of the european patent have changed |
Extension state: BA Payment date: 20120102 Extension state: RS Payment date: 20120102 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: IXXI |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20170623 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20171104 |